The largest database of trusted experimental protocols

Ab228461

Manufactured by Abcam
Sourced in Switzerland

Ab228461 is a laboratory product manufactured by Abcam. It serves as a piece of equipment for use in scientific research and experiments. The core function of this product is to facilitate specific laboratory-based tasks, but a detailed description cannot be provided while maintaining an unbiased and purely factual approach.

Automatically generated - may contain errors

3 protocols using ab228461

1

Antibody Characterization for BRAF Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercial primary antibodies in this paper were as follows: anti-REPO (8D12, DSHB); anti-pH3 (Ser10) (H0412, Millipore); anti-Cleaved-Caspase 3 (9664, Cell Signaling); anti-α tubulin (ab18251, abcam); anti-MEK (8727, Cell Signaling); anti-p-MEK (Ser217/221) (3958, Cell Signaling); anti-ERK (sc-514302, Santa Cruz); anti-p-ERK (T202/Y264) (4370, Cell Signaling); anti-KCNMA1 (sc-374142, Santa Cruz); anti-Ki-67 (9129, Cell Signaling); and anti-GAPDH (ab8245, abcam).
Three BRAF-related antibodies were used in this study: anti-BRAF (sc-5284, Santa Cruz) were used to detect the total levels of BRAF; anti-BRAFV600E specifically recognizing mutated amino acid sequence (ab228461, abcam) were used to detect the levels of BRAFV600E; anti-p-BRAF (S729) specifically recognizing phosphorylated site (ab124794, abcam) were used to detect the levels of BRAF with serine 729 phosphorylation, to measure the BRAF activation levels regardless of the presence of BRAF mutations.
+ Open protocol
+ Expand
2

BRAF(V600E) Immunohistochemistry and Ki67 Analysis in Thyroid Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemical (IHC) staining for BRAFV600E (LZ, TIR) was performed as described before (33 (link)). In brief, we used a mouse monoclonal anti-BRAF (mutated V600E) antibody (VE1) ab228461(Abcam) at a 1:100 dilution and the Novolink Polymer Detection System (250T) (Leica RE7140-K) to detect IHC reaction product. IHC staining was evaluated by three qualified observers (L.Z., T.B., T.I.R.), and full agreement was achieved; there were no specimens interpreted by any observer as potentially false-negative or false-positive. A close correlation between the results of the VE1-based IHC for BRAFV600E and molecular methods of the detection of the BRAFV600E mutation at the DNA level has been reported in a meta-analysis (35 (link)) and confirmed in our previous study using formalin-fixed paraffin-embedded material (36 (link)). Therefore, we assumed the BRAFV600E positivity on IHC was indicative of the BRAFV600E mutation.
The proliferative activity of tumors was evaluated by IHC using Ki67 antibody (clone MIB-1; DAKO, Glostrup, Denmark, 1:100 dilution) in a Ventana BenchMark ULTRA instrument. The Ki67 labeling index (Ki67 LI) was determined with the image-analyzing software (CountσCell, Ki67 antigen Semi-Auto Counter, Seiko Tec LTD, Fukuoka, Japan) in a total of ~1,000 PTC cells (LZ). Image analysis was performed in a blind for the BRAFV600E status manner.
+ Open protocol
+ Expand
3

Immunohistochemical Profiling of Gastric Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 12 samples were subjected to IHC staining. The following markers were examined: p40, human epidermal growth factor receptor 2 (HER2), EBER, programmed death-ligand 1 (PD-L1) CPS, BRAF, and DNA mismatch repair proteins (eg, MLH1, MSH2, MSH6, and PMS2). The following primary antibody probes were utilized: p40 (BC28, Biocare, CA, USA), HER2 (A0485, DAKO, Carpinteria, CA, USA), EBER (PB0589; Biosystems, Muttenz, Switzerland), and BRAF (ab228461; Abcam, Cambridge, UK). DNA mismatch repair proteins were evaluated using the Ventana MMR RxDx Panel (Roche, Tucson, AZ, USA). PD-L1 expression was evaluated using the pharmDx immunohistochemistry assay (PD-L1 IHC 22C3; Agilent, Santa Clara, CA, USA) to determine the CPS. A CPS score of ≥1 was interpreted as positive PD-L1 expression. To compare immunoprofiles between different gastric cancer subtypes, previous studies including the same study group and providing details regarding high microsatellite instability (MSI-H) and PD-L1 expression were reviewed. 13 , 14 Fig. 1 illustrates the patient population and immunoprofile results.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!